Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Lin

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Clinical Lung Cancer|April 15, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted TherapiesSarah Waliany, Yin P Hung, Fawzi Abu Rous, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung CancerTakashi Sakai, Zofia Piotrowska, Charlotte I Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Cell Reports|June 9, 2015
Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast CancerYing Su, Ashim Subedee, Noga Bloushtain-Qimron, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor TherapyOr Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Endocrine-Related Cancer|July 15, 2026
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial dataSteven G Waguespack, Marcia S Brose, Jessica J Lin, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Clinical Lung Cancer|April 15, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted TherapiesSarah Waliany, Yin P Hung, Fawzi Abu Rous, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung CancerTakashi Sakai, Zofia Piotrowska, Charlotte I Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Cell Reports|June 9, 2015
Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast CancerYing Su, Ashim Subedee, Noga Bloushtain-Qimron, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor TherapyOr Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Endocrine-Related Cancer|July 15, 2026
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial dataSteven G Waguespack, Marcia S Brose, Jessica J Lin, et al.
European Journal of Endocrinology|March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaSteven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
Pageof 10